Investigating how immune status affects secondary infections in ARDS patients
Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure
This study is trying to see how a person's immune system affects their chances of getting secondary infections while being treated for severe lung problems called ARDS.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 7 Years and up |
| Sex | All |
| Sponsor | Charite University, Berlin, Germany Academic / other |
| Locations | 1 site (Berlin) |
| Trial ID | NCT06511622 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify patients with acute respiratory distress syndrome (ARDS) who are at risk for secondary infections. Conducted at Charité Universitätsmedizin Berlin, the study will analyze data from patients treated for ARDS between January 2019 and February 2024. It focuses on the relationship between immune status and the development of infectious complications such as ventilator-associated pneumonia and reactivation of Herpes viridae. The findings may help improve patient management and outcomes in severe respiratory failure cases.
Who should consider this trial
Good fit: Ideal candidates include male and female patients diagnosed with ARDS who had their immune status assessed within 48 hours of admission.
Not a fit: Patients who do not have ARDS or those who were not treated at the specified facility during the study period may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better prevention and treatment strategies for secondary infections in ARDS patients.
How similar studies have performed: While there have been studies on ARDS and secondary infections, this specific focus on immune status and its impact on infection rates is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female acute respiratory distress syndrome patients who had an immune status within 48 h of admission * Patients who received intensive care treatment for acute respiratory distress syndrome ward 8i at Charité in the period from 01/2019 to 02/2024 with a maximum follow-up period of 90 days Exclusion Criteria: * None
Where this trial is running
Berlin
- Department of Anesthesiology and Intensive Care Medicine (CCM/CVK), Charité - University Medicine Berlin — Berlin, Germany (Recruiting)
Study contacts
- Study coordinator: Claudia Spies, MD, Prof.
- Email: claudia.spies@charite.de
- Phone: +49 30 450 55 11 02
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.